Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) gained 25.79 Percent and closed its previous trading session at $0.24. The stock traded with the average Volume of 514.79 Million at the end of last session.
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) has the Market Capitalization of 13.79 Million. The Stock has its 52-week High of $2.180 and 52-Week Low of $0.150 and it touched its 52-week high on 01/03/18 and 52-Week Low on 08/10/18
The company reported its last earnings Actual EPS of $-0.05/share. While, the analyst predicted that the company could provide an EPS of $-0.07/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.02/share which shows an Earnings Surprise of 28.6 Percent.
Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 31.73% where SMA50 and SMA200 are 27.58% and -41.6% respectively.
The company shows its Return on Assets (ROA) value of -54.6%. The Return on Equity (ROE) value stands at -62.7%. While it’s Return on Investment (ROI) value is 0%.
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) currently has a Weekly Volatility of 12.37% percent while its Monthly Volatility is at 9.44% percent. While talking about Performance of the Stock, Ohr Pharmaceutical, Inc. currently has a Weekly performance of 15.44%, monthly performance percentage is 59.79 percent, Quarterly performance is -26.15 percent, 6 months performance shows a percent value of -1.44% and Yearly Performance is -69.59 percent.
Ohr Pharmaceutical, Inc. is a pharmaceutical company. It is focused on the development of novel therapeutics for the treatment of cancer cachexia, wet form of age-related macular degeneration and ophthalmic neovascularization disorders. Ohr Pharmaceutical, Inc. is headquartered in New York.